Beatriz Bonaga1, Pedro M Sánchez-Jurado2, Marta Martínez-Reig3, Gabriel Ariza3, Leocadio Rodríguez-Mañas4, Danijela Gnjidic5, Tránsito Salvador1, Pedro Abizanda6. 1. Pharmacy Department, Hospital Clínico Universitario Lozano Blesa de Zaragoza, Zaragoza, Spain. 2. Geriatrics Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain; CIBERFES, Instituto de Salud Carlos III, Madrid, Spain. 3. Geriatrics Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. 4. CIBERFES, Instituto de Salud Carlos III, Madrid, Spain; Geriatrics Department, Hospital Universitario de Getafe, Madrid, Spain. 5. Faculty of Pharmacy and Charles Perkins Center, University of Sydney, Sydney, New South Wales, Australia. 6. Geriatrics Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain; CIBERFES, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: pabizanda@sescam.jccm.
Abstract
BACKGROUND/ OBJECTIVES: To investigate if polypharmacy modifies the association between frailty and health outcomes in older adults. DESIGN: Ongoing cohort study. SETTING: Albacete City, Spain. PARTICIPANTS: A total for 773 participants, 457 women (59.1%), over age 70 years from the FRADEA Study. MEASUREMENTS: Frailty phenotype, polypharmacy considered as the chronic use of 5 or more drugs, and comorbidity were collected at the baseline visit. Participants were categorized in 6 groups according to frailty and polypharmacy, and were followed up for 5.5 years (mean 1057 days, range 1-2007). Mortality or incident disability in basic activities of daily living was considered the main outcome variable. Hospitalization and visits to the emergency department were also recorded. The adjusted association between combined frailty status and polypharmacy with outcome variables was analyzed. RESULTS: The mean age of study population was 78.5 years. In this population, we identified a 15.3% (n = 118) of frail with polypharmacy, 3.4% (n = 26) of frail without polypharmacy, 35.3% (n = 273) of prefrail with polypharmacy, 20.3% (n = 157) of prefrail without polypharmacy, 10.3% (n = 80) of nonfrail with polypharmacy, and 15.4% (n = 119) of nonfrail participants without polypharmacy. Participants with frailty and polypharmacy had a higher adjusted risk of mortality or incident disability [odds ratio (OR) 5.3; 95% confidence interval (CI) 2.3-12.5] and hospitalization (OR 2.3; 95% CI 1.2-4.4), compared with those without frailty and polypharmacy. Frail and prefrail participants with polypharmacy had a higher adjusted mortality risk compared with the nonfrail without polypharmacy, hazard ratio 5.8 (95% CI 1.9-17.5) and hazard ratio 3.1 (95% CI 1.1-9.1), respectively. CONCLUSIONS: Polypharmacy is associated with mortality, incident disability, hospitalization, and emergency department visits in frail and prefrail older adults, but not in nonfrail adults. Polypharmacy should be monitored in these patient subgroups to optimize health outcomes.
BACKGROUND/ OBJECTIVES: To investigate if polypharmacy modifies the association between frailty and health outcomes in older adults. DESIGN: Ongoing cohort study. SETTING: Albacete City, Spain. PARTICIPANTS: A total for 773 participants, 457 women (59.1%), over age 70 years from the FRADEA Study. MEASUREMENTS: Frailty phenotype, polypharmacy considered as the chronic use of 5 or more drugs, and comorbidity were collected at the baseline visit. Participants were categorized in 6 groups according to frailty and polypharmacy, and were followed up for 5.5 years (mean 1057 days, range 1-2007). Mortality or incident disability in basic activities of daily living was considered the main outcome variable. Hospitalization and visits to the emergency department were also recorded. The adjusted association between combined frailty status and polypharmacy with outcome variables was analyzed. RESULTS: The mean age of study population was 78.5 years. In this population, we identified a 15.3% (n = 118) of frail with polypharmacy, 3.4% (n = 26) of frail without polypharmacy, 35.3% (n = 273) of prefrail with polypharmacy, 20.3% (n = 157) of prefrail without polypharmacy, 10.3% (n = 80) of nonfrail with polypharmacy, and 15.4% (n = 119) of nonfrail participants without polypharmacy. Participants with frailty and polypharmacy had a higher adjusted risk of mortality or incident disability [odds ratio (OR) 5.3; 95% confidence interval (CI) 2.3-12.5] and hospitalization (OR 2.3; 95% CI 1.2-4.4), compared with those without frailty and polypharmacy. Frail and prefrail participants with polypharmacy had a higher adjusted mortality risk compared with the nonfrail without polypharmacy, hazard ratio 5.8 (95% CI 1.9-17.5) and hazard ratio 3.1 (95% CI 1.1-9.1), respectively. CONCLUSIONS: Polypharmacy is associated with mortality, incident disability, hospitalization, and emergency department visits in frail and prefrail older adults, but not in nonfrail adults. Polypharmacy should be monitored in these patient subgroups to optimize health outcomes.
Authors: María Pérez Fernández; Patricia Martínez Miguel; Hao Ying; Christine E Haugen; Nadia M Chu; Diego María Rodríguez Puyol; Leocadio Rodríguez-Mañas; Silas P Norman; Jeremy D Walston; Dorry L Segev; Mara A McAdams-DeMarco Journal: Am J Nephrol Date: 2019-01-09 Impact factor: 3.754
Authors: Meredith L Wallace; Daniel J Buysse; Susan Redline; Katie L Stone; Kristine Ensrud; Yue Leng; Sonia Ancoli-Israel; Martica H Hall Journal: J Gerontol A Biol Sci Med Sci Date: 2019-11-13 Impact factor: 6.053
Authors: M Gutiérrez-Valencia; M Izquierdo; M Cesari; Á Casas-Herrero; M Inzitari; N Martínez-Velilla Journal: Br J Clin Pharmacol Date: 2018-05-03 Impact factor: 4.335
Authors: Emanuele Rocco Villani; Davide Liborio Vetrano; Rosa Liperoti; Katie Palmer; Michael Denkinger; Henriëtte G van der Roest; Roberto Bernabei; Graziano Onder Journal: Aging Clin Exp Res Date: 2021-02-15 Impact factor: 3.636